ESMO: European Society for Medical Oncology

Conference Coverage

Osimertinib improves survival in advanced NSCLC

BARCELONA – Osimertinib is the first TKI to show a survival advantage over another in advanced non–small cell lung cancer, FLAURA investigators...

Conference Coverage

OAK: Atezolizumab grows OS in advanced NSCLC

COPENHAGEN – The checkpoint inhibitor atezolizumab improved overall survival of advanced non–small-cell lung cancer, compared with docetaxel.

News

Adjuvant vaccine fails in NSCLC

Key clinical point: Adjuvant lung cancer vaccination failed to improve disease-free survival in early-stage non–small cell lung cancer. Major...

Pages